About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
Health Care and Law
Supreme Court Finds That FDA Approval Does Not Stand In the Way
In the recent case of Wyeth v. Levine, the drug company unsuccessfully appealed an award to a patient who had been harmed by Phenergan—even though the FDA had approved this injectable drug. Dr. Field reviews this precedent-setting case.
Robert I. Field, JD, MPH, PhD
But American Recovery and Reinvestment Act Gives Pharmacies Short Shrift
The advent of electronic prescribing was supposed to be a large part of the cure for improving patient outcomes and reducing prescription errors, but only a fraction of scripts are being sent electronically. Independent and hospital pharmacies continue to lag behind the technology wave because of the expense involved.
Clinical and Financial Implications
Although H.P. Acthar Gel has been beneficial in MS, spasms, and adrenal testing, its high cost has led to a larger role for alternatives like cosyntropin and steroids.
Jacob Gettig, PharmD, MPH, BCPS; Joseph P. Cummings, PhD; and Karl Matuszewski, MS, PharmD
Summaries include clinical trials involving statins; eptifibatide; non-statins (Zetia); and a "polypill" containing antihypertensive agents, a statin, and aspirin (PolyCap).
Topics include Afinitor for renal cell carcinoma; Ixiaro vaccine to prevent Japanese encephalitis; and ATryn, an antithrombin product engineered from goats.
Marvin M. Goldenberg, PhD, RPh, MS
David B. Nash, MD, MBA, discusses how an arcane system of pricing determines which medications end up on formularies and how benchmarks to establish best practices can reduce drug costs.
David B. Nash, MD, MBA
Matthew Grissinger, RPh, FASCP, provides instructions on the correct use of document-imaging technology in sending prescriptions to pharmacies.
Matthew Grissinger, RPh, FASCP
Report and Lawsuit Settlement Might Lead to New Formula
Stephen Barlas discusses the differences between Medicaid and Medicare Part D in their dispensing fees to pharmacies for generic drugs.
From Afinitor (everolimus) to Raptiva (efalizumab), P&T presents the latest information about FDA approvals, new indications, and recalls.
An Inside Look at the Oral Direct Factor Xa Inhibitor
The authors review rivaroxaban (Xarelto), an anti-coagulant for preventing thromboembolic disease.
Younos Abdulsattar, PharmD Candidate, Rahul Bhambri, PharmD Candidate, and Anna Nogid, BS, PharmD, BCPS